The HEBP1 Knockout SK-HEP-1 Polyclonal Cells product comprises a polyclonal population of SK-HEP-1 human liver adenocarcinoma cells edited via CRISPR/Cas9-mediated disruption of the HEBP1 gene. This knockout model is provided as a heterogeneous pool of edited cells, enabling studies of HEBP1 function without clonal selection artifacts. The polyclonal format preserves genetic diversity while achieving targeted gene disruption across the population, offering a robust tool for loss-of-function analyses in a disease-relevant hepatic context.
The SK-HEP-1 host cell line is an adherent human liver adenocarcinoma line derived from a male patient, notable for its concurrent endothelial and hepatocyte characteristics. This model expresses both hepatic markers and endothelial adhesion molecules, making it uniquely suited for investigating hepatocellular carcinoma biology and metastatic dissemination. Its dual nature facilitates studies on cancer cell plasticity, epithelial-to-endothelial transition, and angiogenesis. The SK-HEP-1 cell line is widely used due to its metastatic potential and utility in modeling liver-to-lung metastasis in vivo.
HEBP1 encodes a cytoplasmic heme-binding protein that buffers free heme to prevent oxidative damage, thereby maintaining redox equilibrium. Under elevated heme or oxidative stress, it is regulated by transcription factors NRF2 and HIF1A, and by GATA1. HEBP1 interacts directly with heme, porphyrins, and mitochondrial proteins to control heme bioavailability. Its disruption leads to increased free heme, causing ROS accumulation, mitochondrial depolarization, and cytochrome c release. This shifts the BCL2 family balance toward pro-apoptotic BAX, opening the mitochondrial permeability transition pore and activating CASP3-mediated apoptosis. Thus, HEBP1 serves as a fulcrum connecting heme metabolism to intrinsic cell death pathways.
In SK-HEP-1 liver cancer cells, HEBP1 knockout is predicted to sensitize them to heme-induced apoptosis and amplify oxidative stress-mediated damage. Given the liver’s central role in heme metabolism and the frequent dysregulation of heme homeostasis in hepatocellular carcinoma, this polyclonal knockout model provides a highly relevant platform to study the impact of heme buffering on mitochondrial integrity and cell survival. It also offers potential for probing drug resistance mechanisms in liver cancers, where impaired apoptosis contributes to chemoresistance.
Researchers can utilize this polyclonal knockout population for functional assays including apoptosis detection by Annexin V/PI, ROS measurement with DCFDA, mitochondrial membrane potential assessment with JC-1, and knockout confirmation via RT-qPCR and western blotting. Cell viability testing under heme or oxidative challenge clarifies HEBP1??s protective roles. This model is ideal for studying heme metabolism disorders, liver cancer apoptosis, and heme-targeted therapeutics. For further information or custom inquiries, please contact Ascent Research.
